269. 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群 Pyogenic arthritis Clinical trials / Disease details


臨床試験数 : 23 薬物数 : 30 - (DrugBank : 12) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 106

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-003273-21-PL
(EUCTR)
09/11/202008/09/2020NAOpen label exploratory phase IIa trial to investigate the safety and efficacy of IFX-1 in treating subjects with Pyoderma Gangrenosum (OPTIMA). - Exploratory study of IFX-1 in Subjects with Pyoderma Gangrenosum Pyoderma gangrenosum
MedDRA version: 20.0;Level: PT;Classification code 10037635;Term: Pyoderma gangrenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: IFX-1
Other descriptive name: Anti-(complement C5a) IgG4 chimeric monoclonal antibody
Product Name: IFX-1
Other descriptive name: Anti-(complement C5a) IgG4 chimeric monoclonal antibody
InflaRx GmbHNULLNot RecruitingFemale: yes
Male: yes
18Phase 2United States;Poland